Cagrilintide is not FDA approved
peo, B
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib
performed a cross-trial analysis using data from clinical trials of GLP-1RAs (ELIXA, LEADER, SUSTAIN-6, EXSCEL, HARMONY, REWIND, PIONEER-6 [59], and AMPLITUDE-O), SGLT2is (CANVAS and CREDENCE), and finerenone (FIDELIO-DKD and FIGARO-DKD) to estimate the effects of the triple combination therapy of GLP-1RA, SGLT2i, and finerenone using the actuarial method [60]
Advances in Mind-Body Medicine, 30 (1), 4-11
However, whether the universality of this criterion is limited by ethnicity, region and gender remains to be further studied